Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Pharmaceuticals (Basel) 2023;16:994.ArticlePubMedPMC 82
Britain's National Institute for Health and Care Excellence (NICE) has officially greenlit Teplizumab (Tzield) for use in England and Wales
WuHGuYMengGZhangQLiuLZhangSet al
Insight into your patients genetics and drug metabolism profile, specifically MTHFR , can allow for personalized treatment plans and medication choices
In this context, GLP-1based pharmacotherapies have emerged as a valuable adjunct to lifestyle modification, with growing evidence supporting their role in improving weight-related and cardiometabolic outcomesThis review has examined the mechanisms of action, clinical efficacy, safety considerations, and future directions of GLP-1 single, dual, and triple agonists, with a focus on their potential relevance to adolescent obesity management
